|
|
市场分析报告
|
Horizon Pharma PLC Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... ) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized ...
Cystinosis Market - A Global and Regional Analysis: Focus on Type, Drug Class, and Region - Analysis and Forecast, 2025-2035 Hard copy option is available on any of the options above at an additional charge of $500. Please email us at
Nonalcoholic Steatohepatitis: KOL Insight ... sector, Raptor Pharmaceuticals' delayed-release cysteamine bitartrate. The upcoming products vary in their ...
Leigh Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major leigh syndrome markets reached a value of US$ 105.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 175.1 Million by 2034, exhibiting a growth rate (CAGR) of 4.76% during 2024-2034. The Leigh syndrome market has been ...
|
|
|
|